Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.

Pharmaceutical

Orchard Therapeutics PLC

Bobby Gaspar

Braden Parker

Nicoletta Loggia

Fulvio Mavilio

Leslie Meltzer

Frank Thomas

John Cerio

The Clinical Development and Operations team at Orchard Therapeutics PLC is responsible for designing, implementing, and managing clinical trials for gene and cell therapies targeting rare diseases. This team ensures that all clinical activities comply with regulatory standards, optimizes operational strategies, and oversees data management to facilitate successful product development and commercialization. By collaborating closely with cross-functional teams, they aim to deliver transformative therapies to patients efficiently and effectively.

Clinical Development and Operations

Medical Affairs and Regulatory Science

Leadership Team

Clinical Development and Operations

About

Team members